A nose-brain pathway for psychotropic peptides: Evidence from a brain evoked potential study with cholecystokinin

Psychoneuroendocrinology

Volumn 21, Issue 6, 1996, Pages 559-572

  Pietrowsky, Reinhard ^a   Thiemann, Andrea ^a   Kern, Werner ^a   Fehm, Horst L ^a   Born, Jan ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

auditory evoked potential; blood brain barrier; CCK; cholecystokinin; human; nose brain barrier; P3

Indexed keywords

CHOLECYSTOKININ; CORTICOTROPIN; HYDROCORTISONE;

ADULT; ARTICLE; ATTENTION; BRAIN; EVOKED AUDITORY RESPONSE; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRANASAL DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ADRENOCORTICOTROPIC HORMONE; ADULT; AROUSAL; BRAIN; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; FEMALE; HUMANS; HYDROCORTISONE; INJECTIONS, INTRAVENOUS; MALE; SINCALIDE;

EID: 0030209441     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(96)00012-1     Document Type: Article

References (48)

1. Baker H, Spencer RF (1986) Transneuronal transport of peroxidase-conjugated wheat germ agglutinin (WGA-HRP) from the olfactory epithelium to the brain of the adult rat. Exp Brain Res 63:461-473.
2. Balin BJ, Broadwell RD, Salcman M, El-Kalliny M (1986) Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J Comp Neurol 251:260-280.
3. Banks WA, Kastin AJ (1987) Saturable transport of peptides across the blood-brain barrier. Life Sci 41:1319-1338.
4. Baribeau-Braun J, Picton TW, Gosselin J (1983) Schizophrenia: A neurophysiological evaluation of abnormal information processing. Science 219:874-876.
5. Barnett EM, Perlman S (1993) The olfactory nerve and not the trigeminal nerve is the major site of CNS entry for mouse hepatitis virus, strain JHM. Virology 194:185-191.
6. Barthold SW (1988) Olfactory neural pathway in mouse hepatitis virus nasoencephalitis. Acta Neuropatho (Berlin) 76:502-506.
7. Bouras C, Magistretti PJ, Morrison JH (1986) An immunohistochemical study of six biologically active peptides in the human brain. Hum Neurobiol 5:213-226.
8. Carter DA, Lightman SL (1987) A role for the area postrema in mediating cholecystokinin-stimulated oxytocin secretion. Brain Res 435:327-330.
9. Dietl MM, Probst A, Palacios JM (1987) On the distribution of cholecystokinin receptor binding sites in the human brain: an autoradiographic study. Synapse 1:169-183.
10. Eseri MM, Tomlinson AH (1984) Herpes simplex encephalitis. J Neurol Sci 64:213-217.
11. Freeman AS, Chiodo LA, Lentz SI, Wade K, Bannon MJ (1991) Release of cholecystokinin from rat midbrain slices and modulatory effect of D2 DA-receptor stimulation. Brain Res 555:281-287.
12. García-Velasco J, Mondragon M (1991) The incidence of the vomeronasal organ in 1000 human subjects and its possible clinical significance. J Steroid Biochem Mol Biol 39:561-563.
13. Höcker M, Schmidt WE, Creuzfeldt W, Choudhury AR, Nustede R, Schafmayer A, Fölsch UR (1992) Determination of plasma cholecystokinin (CCK) concentrations by bio-assay and radioimmunoassay in man. A critical evaluation. Regul Pept 37:255-269.
14. Hökfelt T, Rehfeld JF, Skirboll L, Ivemark B, Goldstein M, Markey K (1980) Evidence for coexistence of dopamine and CCK in mesolimbic neurons. Nature 285:476-478.
15. Itaya SK (1987) Anterograde transsynaptic transport of WGA-HRP in rat olfactory pathways. Brain Res 409:205-214.
16. Johnson R Jr, Donchin E (1985) Second thoughts: Multiple P3s to emotional stimuli and their theoretical significance. Psychophysiology 23:684-694.
17. Jurna I, Zetler G (1981) Antinociceptive effect of centrally administered caerulein and cholecystokinin octapeptide (CCK-8). Europ J Pharmacol 73:323-331.
18. Karlsson R, Lindèn A, von Schoultz B (1992) Suppression of 24-hour cholecystokinin secretion by oral contraceptives. Am J Obstetrics Gynecol 167:58-59.
19. Lotstra F, Verbanck P, Mendlewicz J, Vanderhaeghen JJ (1984) No evidence of antipsychotic effect of caerulein in schizophrenic patients free of neuroleptics: a double-blind cross-over study. Biol Psychiatry 19:877-882.
20. Mercer JG, Lawrence CB (1992) Selectivity of cholecystokinin (CCK) receptor antagonists, MK-329 and L-365,260, for axonally-transported CCK binding sites on the rat vagus nerve. Neurosci Lett 137:229-231.
21. Meredith M, Fernandez-Fewell G (1994) Vomeronasal system, LHRH, and sex behavior. Psychoneuroendocrinology 19:657-672.
22. Montgomery SA, Green MCD (1988) The use of cholecystokinin in schizophrenia: a review. Psychol Med 18:593-603.
23. Monti-Bloch L, Jennings-White C, Dolberg DS, Berliner DL (1994) The human vomeronasal system. Psychoneuroendocrinology 19:673-686.
24. Morales JA, Herzog S, Kompter C, Frese K, Rott R (1988) Axonal transport of Borna disease virus along olfactory pathways in spontaneously and experimentally infected rats. Med Microbiol Immunol 177:51-68.
25. Nair NPV, Bloom DM, Nestoros JN, Schwartz G (1983) Therapeutic efficacy of cholecystokinin in neuroleptic-resistant schizophrenic subjects. Psychopharmacol Bull 19:134-136.
26. Oeth KM, Lewis DA (1992) Cholecystokinin- and dopamine-containing mesencephalic neurons provide distinct projections to monkey prefrontal cortex. Neurosci Lett 145:87-92.
27. Oro AE, Simerly RB, Swanson LW (1988) Estrous cycle variations in levels of cholecystokinin immunoreactivity within cells in three interconnected sexually dimorphic forebrain nuclei. Neuroendocrinology 47:225-235.
28. Pardridge WM, Eisenberg J, Yang J (1985) Human blood-brain barrier insulin receptor. J Neurochem 44:1771-1778.
29. Perlman S, Evans G, Afifi A (1990) Effects of olfactory bulb ablation on spread of a neurotropic coronavirus into the mouse brain. J Exp Med 172:1127-1132.
30. Pietrowsky R, Fehm HL, Er A, Bathelt B, Born J (1990) Influences of the cholecystokinin analog ceruletide on human sleep and evoked potentials. Neuropsychobiology 23:41-47.
31. Pietrowsky R, Schiemann C, Fehm HL, Born J (1993) The P2 amplitude of the auditory evoked potential is diminished by the cholecystokinin-analog ceruletide. J Psychophysiol 7:3-10.
32. Pietrowsky R, Strüben C, Mölle M, Fehm HL, Born J (1996) Brain potential changes after intranasal versus intravenous administration of vasopressin: Evidence for a direct nose-brain pathway for peptide effects in man. Biol Psychiat 39:241-250.
33. Pribram KH, Luria AR (1973) Psychophysiology of the Frontal Lobes. Academic Press, New York.
34. Pycock CH, Carter CJ, Kerwin RW (1980) Effect of 6-hydroxydopamine lesions of the medial prefrontal cortex on neurotransmitter systems in subcortical sites in the rat. J Neurochem 34:91-99.
35. Schreiber H, Stolz-Born G, Pietrowsky R, Kornhuber HH, Fehm HL, Born J (1995) Improved event-related potential signs of selective attention after the cholecystokinin-analog ceruletide in healthy controls. Biol Psychiat 37:702-712.
36. Shankar V, Kao M, Hamir AN, Sheng H, Koprowsi H, Ditsz-schold B (1992) Kinetics of virus spread and changes in levels of several cytokine mRNAs in the brain after intranasal infection of rats with Borna disease virus. J Virology 66:992-998.
37. Smith GP, Gibbs J (1984) Gut peptides and postprandial satiety. Fed Proceed 43:2889-2892.
38. Smith GP, Jerome C, Cushin BJ, Eterno R, Simansky KJ (1981) Abdominal vagotomy blocks the satiety effect of cholecystokinin in the rat. Science 213:1036-1037.
39. Späth-Schwalbe E, Pieroth L, Pietrowsky R, Born J, Fehm HL (1988) Stimulation of the pituitary adrenocortical system in man by cerulein, a cholecystokinin-8-like peptide. Clin Physiol Biochem 6:316-320.
40. Stroop WG, Rock DL, Fraser NW (1984) Localization of herpes simplex virus in the trigeminal and olfactory systems of the mouse central nervous system during acute and latent infection. Lab Invest 51:27-38.
41. Stuss DT, Benson DF (1986) The Frontal Lobes. Raven Press, New York.
42. Sutton S, Ruchkin DS (1984) The late positive complex. In: Karrer R, Cohen J, Tueting P (Eds) Brain and Information: Event-related Potentials, New York Academy of Science, New York, pp 1-23.
43. Tamminga CA, Littman RL, Alphs LD, Chase TN, Taker GK, Wagman AM (1986) Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies. Psychopharmacology 88:387-391.
44. Van der Kooy D (1984) Area postrema. Site where cholecystokinin acts to decrease food intake. Brain Res 295:345-347.
45. Van Ree JM, Verhoeven WMA, Brouwer GH, De Wied D (1984) Ceruletide resembles antipsychotics in rats and schizophrenic patients. Neuropsychobiology 12:4-8.
46. Weindl A, Sofroniew MV (1981) Relation of neuropeptides to mammalian circumventricular organs. In: Martin JB, Reichlin S, Bick KL (Eds) Neurosecretion and Brain Function. Raven Press, New York, pp 303-320..
47. Woods DL, Knight RT (1986) Electrophysiologic evidence of increased distractability after dorsolateral pre-frontal lesions. Neurology 36:212-216.
48. Zlokovic BV, Segal MB, Davson H, Lipovac MN, Hyman S, McComb JG (1990) Circulating neuroactive peptides and the blood brain and blood cerebrospinal fluid barrier. Endocrinol Exp 24:9-17.